BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

509 related articles for article (PubMed ID: 31471491)

  • 1. Comprehensive genomic profiling of glioblastoma tumors, BTICs, and xenografts reveals stability and adaptation to growth environments.
    Shen Y; Grisdale CJ; Islam SA; Bose P; Lever J; Zhao EY; Grinshtein N; Ma Y; Mungall AJ; Moore RA; Lun X; Senger DL; Robbins SM; Wang AY; MacIsaac JL; Kobor MS; Luchman HA; Weiss S; Chan JA; Blough MD; Kaplan DR; Cairncross JG; Marra MA; Jones SJM
    Proc Natl Acad Sci U S A; 2019 Sep; 116(38):19098-19108. PubMed ID: 31471491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bmi1 regulates human glioblastoma stem cells through activation of differential gene networks in CD133+ brain tumor initiating cells.
    Vora P; Seyfrid M; Venugopal C; Qazi MA; Salim S; Isserlin R; Subapanditha M; O'Farrell E; Mahendram S; Singh M; Bakhshinyan D; Chokshi C; McFarlane N; Dvorkin-Gheva A; Brown KR; Murty N; Moffat J; Bader GD; Singh SK
    J Neurooncol; 2019 Jul; 143(3):417-428. PubMed ID: 31115870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. On-target JAK2/STAT3 inhibition slows disease progression in orthotopic xenografts of human glioblastoma brain tumor stem cells.
    Stechishin OD; Luchman HA; Ruan Y; Blough MD; Nguyen SA; Kelly JJ; Cairncross JG; Weiss S
    Neuro Oncol; 2013 Feb; 15(2):198-207. PubMed ID: 23262510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fibrinogen in the glioblastoma microenvironment contributes to the invasiveness of brain tumor-initiating cells.
    Dzikowski L; Mirzaei R; Sarkar S; Kumar M; Bose P; Bellail A; Hao C; Yong VW
    Brain Pathol; 2021 Sep; 31(5):e12947. PubMed ID: 33694259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. REST-DRD2 mechanism impacts glioblastoma stem cell-mediated tumorigenesis.
    Marisetty AL; Lu L; Veo BL; Liu B; Coarfa C; Kamal MM; Kassem DH; Irshad K; Lu Y; Gumin J; Henry V; Paulucci-Holthauzen A; Rao G; Baladandayuthapani V; Lang FF; Fuller GN; Majumder S
    Neuro Oncol; 2019 Jun; 21(6):775-785. PubMed ID: 30953587
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative genomic and genetic analysis of glioblastoma-derived brain tumor-initiating cells and their parent tumors.
    Davis B; Shen Y; Poon CC; Luchman HA; Stechishin OD; Pontifex CS; Wu W; Kelly JJ; Blough MD;
    Neuro Oncol; 2016 Mar; 18(3):350-60. PubMed ID: 26245525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor microenvironment tenascin-C promotes glioblastoma invasion and negatively regulates tumor proliferation.
    Xia S; Lal B; Tung B; Wang S; Goodwin CR; Laterra J
    Neuro Oncol; 2016 Apr; 18(4):507-17. PubMed ID: 26320116
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reactive species balance via GTP cyclohydrolase I regulates glioblastoma growth and tumor initiating cell maintenance.
    Tran AN; Walker K; Harrison DG; Chen W; Mobley J; Hocevar L; Hackney JR; Sedaka RS; Pollock JS; Goldberg MS; Hambardzumyan D; Cooper SJ; Gillespie Y; Hjelmeland AB
    Neuro Oncol; 2018 Jul; 20(8):1055-1067. PubMed ID: 29409010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treating brain tumor-initiating cells using a combination of myxoma virus and rapamycin.
    Zemp FJ; Lun X; McKenzie BA; Zhou H; Maxwell L; Sun B; Kelly JJ; Stechishin O; Luchman A; Weiss S; Cairncross JG; Hamilton MG; Rabinovich BA; Rahman MM; Mohamed MR; Smallwood S; Senger DL; Bell J; McFadden G; Forsyth PA
    Neuro Oncol; 2013 Jul; 15(7):904-20. PubMed ID: 23585629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dissecting inherent intratumor heterogeneity in patient-derived glioblastoma culture models.
    Teng J; da Hora CC; Kantar RS; Nakano I; Wakimoto H; Batchelor TT; Chiocca EA; Badr CE; Tannous BA
    Neuro Oncol; 2017 Jun; 19(6):820-832. PubMed ID: 28062830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stattic and metformin inhibit brain tumor initiating cells by reducing STAT3-phosphorylation.
    Leidgens V; Proske J; Rauer L; Moeckel S; Renner K; Bogdahn U; Riemenschneider MJ; Proescholdt M; Vollmann-Zwerenz A; Hau P; Seliger C
    Oncotarget; 2017 Jan; 8(5):8250-8263. PubMed ID: 28030813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiation Drives the Evolution of Orthotopic Xenografts Initiated from Glioblastoma Stem-like Cells.
    McAbee JH; Rath BH; Valdez K; Young DL; Wu X; Shankavaram UT; Camphausen K; Tofilon PJ
    Cancer Res; 2019 Dec; 79(23):6032-6043. PubMed ID: 31615806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene signatures of quiescent glioblastoma cells reveal mesenchymal shift and interactions with niche microenvironment.
    Tejero R; Huang Y; Katsyv I; Kluge M; Lin JY; Tome-Garcia J; Daviaud N; Wang Y; Zhang B; Tsankova NM; Friedel CC; Zou H; Friedel RH
    EBioMedicine; 2019 Apr; 42():252-269. PubMed ID: 30952620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glioblastomas acquire myeloid-affiliated transcriptional programs via epigenetic immunoediting to elicit immune evasion.
    Gangoso E; Southgate B; Bradley L; Rus S; Galvez-Cancino F; McGivern N; Güç E; Kapourani CA; Byron A; Ferguson KM; Alfazema N; Morrison G; Grant V; Blin C; Sou I; Marques-Torrejon MA; Conde L; Parrinello S; Herrero J; Beck S; Brandner S; Brennan PM; Bertone P; Pollard JW; Quezada SA; Sproul D; Frame MC; Serrels A; Pollard SM
    Cell; 2021 Apr; 184(9):2454-2470.e26. PubMed ID: 33857425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular heterogeneity in a patient-derived glioblastoma xenoline is regulated by different cancer stem cell populations.
    Garner JM; Ellison DW; Finkelstein D; Ganguly D; Du Z; Sims M; Yang CH; Interiano RB; Davidoff AM; Pfeffer LM
    PLoS One; 2015; 10(5):e0125838. PubMed ID: 25955030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The TNF receptor family member Fn14 is highly expressed in recurrent glioblastoma and in GBM patient-derived xenografts with acquired temozolomide resistance.
    Hersh DS; Harder BG; Roos A; Peng S; Heath JE; Legesse T; Kim AJ; Woodworth GF; Tran NL; Winkles JA
    Neuro Oncol; 2018 Sep; 20(10):1321-1330. PubMed ID: 29897522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
    Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S
    Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microenvironmental regulation of glioblastoma radioresponse.
    Jamal M; Rath BH; Williams ES; Camphausen K; Tofilon PJ
    Clin Cancer Res; 2010 Dec; 16(24):6049-59. PubMed ID: 21037023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined expressional analysis, bioinformatics and targeted proteomics identify new potential therapeutic targets in glioblastoma stem cells.
    Stangeland B; Mughal AA; Grieg Z; Sandberg CJ; Joel M; Nygård S; Meling T; Murrell W; Vik Mo EO; Langmoen IA
    Oncotarget; 2015 Sep; 6(28):26192-215. PubMed ID: 26295306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An RNAi screen identifies TRRAP as a regulator of brain tumor-initiating cell differentiation.
    Wurdak H; Zhu S; Romero A; Lorger M; Watson J; Chiang CY; Zhang J; Natu VS; Lairson LL; Walker JR; Trussell CM; Harsh GR; Vogel H; Felding-Habermann B; Orth AP; Miraglia LJ; Rines DR; Skirboll SL; Schultz PG
    Cell Stem Cell; 2010 Jan; 6(1):37-47. PubMed ID: 20085741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.